Christopher G Tarolli1, Grace A Zimmerman1, Peggy Auinger1, Scott McIntosh1, Robert K Horowitz1, Benzi M Kluger1, E Ray Dorsey1, Robert G Holloway1. 1. Department of Neurology (CGT, GAZ, RGH), University of Rochester Medical Center, NY; Center for Health + Technology (CGT, PA, ERD), University of Rochester Medical Center, NY; Department of Public Health Sciences (SM), University of Rochester Medical Center, NY; Department of Internal Medicine (RKH), Palliative Care Division, University of Rochester Medical Center, NY; and Department of Neurology (BMK), University of Colorado Anschutz Medical Campus, Aurora.
Abstract
OBJECTIVE: To explore disease burden in Parkinson disease (PD) by evaluating the prevalence of symptoms and key disease milestones (critical events, e.g., hospitalization or frequent falls) and their association with quality of life (QOL) in those with PD. METHODS: We created and pretested an online needs assessment survey to evaluate the clinical characteristics, QOL, symptom prevalence, and critical event frequency among those with PD. We recruited individuals with self-reported Hoehn and Yahr stage II-V PD through online postings and email through the Davis Phinney Foundation. We used logistic regression to evaluate the association between a large number of uncontrolled symptoms and events on QOL. RESULTS: A total of 612 individuals (mean age 70.1 years, 49.8% women) completed the survey. Among respondents, 13.6% reported poor QOL. Nearly 20% of respondents reported >3 falls, and 15% of respondents had been hospitalized over the previous 6 months. Participants had an average of 5.1 uncontrolled symptoms, with 86.1% of respondents reporting at least 1 uncontrolled symptom; more than 10% of respondents reported >10 uncontrolled symptoms. Depression, confusion, pain, and bothersome hallucinations were associated with poor QOL among the cohort. CONCLUSIONS: In this national survey of individuals with PD, we identified poor QOL, frequent critical events, and numerous uncontrolled symptoms among a substantial proportion of respondents. Although motor symptoms were common, only nonmotor symptoms were associated with poor QOL. Many of these symptoms and events are treatable or preventable, highlighting the need for better identification and management to improve QOL among those with PD.
OBJECTIVE: To explore disease burden in Parkinson disease (PD) by evaluating the prevalence of symptoms and key disease milestones (critical events, e.g., hospitalization or frequent falls) and their association with quality of life (QOL) in those with PD. METHODS: We created and pretested an online needs assessment survey to evaluate the clinical characteristics, QOL, symptom prevalence, and critical event frequency among those with PD. We recruited individuals with self-reported Hoehn and Yahr stage II-V PD through online postings and email through the Davis Phinney Foundation. We used logistic regression to evaluate the association between a large number of uncontrolled symptoms and events on QOL. RESULTS: A total of 612 individuals (mean age 70.1 years, 49.8% women) completed the survey. Among respondents, 13.6% reported poor QOL. Nearly 20% of respondents reported >3 falls, and 15% of respondents had been hospitalized over the previous 6 months. Participants had an average of 5.1 uncontrolled symptoms, with 86.1% of respondents reporting at least 1 uncontrolled symptom; more than 10% of respondents reported >10 uncontrolled symptoms. Depression, confusion, pain, and bothersome hallucinations were associated with poor QOL among the cohort. CONCLUSIONS: In this national survey of individuals with PD, we identified poor QOL, frequent critical events, and numerous uncontrolled symptoms among a substantial proportion of respondents. Although motor symptoms were common, only nonmotor symptoms were associated with poor QOL. Many of these symptoms and events are treatable or preventable, highlighting the need for better identification and management to improve QOL among those with PD.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jennifer S A M Reijnders; Uwe Ehrt; Wim E J Weber; Dag Aarsland; Albert F G Leentjens Journal: Mov Disord Date: 2008-01-30 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Amy Werremeyer; Jolene Bostwick; Carla Cobb; Tera D Moore; Susie H Park; Cristofer Price; Jerry McKee Journal: Ment Health Clin Date: 2020-11-05
Authors: Robert S Eisinger; Bonnie M Scott; Anh Le; Elena M Torres Ponce; Joseph Lanese; Christopher Hundley; Brawn Nelson; Tasmeah Ravy; Janine Lopes; Sable Thompson; Sneha Sathish; Rebecca L O'Connell; Michael S Okun; Dawn Bowers; Aysegul Gunduz Journal: Sci Rep Date: 2020-08-10 Impact factor: 4.379
Authors: Megan C Bakeberg; Anastazja M Gorecki; Jade E Kenna; Alexa Jefferson; Michelle Byrnes; Soumya Ghosh; Malcolm K Horne; Sarah McGregor; Rick Stell; Sue Walters; Frank L Mastaglia; Ryan S Anderton Journal: Front Aging Neurosci Date: 2021-06-11 Impact factor: 5.750